The sales of analgesic medicines in Ireland have shown varying trends over the past decade. From 2013 to 2019, the market experienced both growth and decline, with notable dips in 2017 and 2018. Since 2020, the sales figures have stabilized with modest improvements, standing at 56.0 million Euros in both 2023 and expectedly in 2024. The year-on-year variations over the past two years were minimal, reflecting a steady state in sales figures. Specifically, the 2023 sales value indicates a stabilization phase.
Over the last five years, the Compound Annual Growth Rate (CAGR) averages 0.73%, suggesting a modest upward trend. However, forecasts from 2024 to 2028 predict no significant growth, with the market expected to remain stable at 56.0 million Euros, yielding a forecasted five-year CAGR of 0%.
Future trends to watch for:
- Potential impact of new analgesic products entering the market
- Changes in healthcare policies and their effect on sales
- Consumer preferences towards non-pharmaceutical pain management solutions
- Technological advancements in pain management therapies
